Cell cycling throttles epithelial--mesenchymal transition
- 1University of Southern California
Abstract
Cell cycle phase is an understudied source of variation in gene expression. EMT is a case in point: this cell state transition that drives metastasis has been studied widely across tissue, stimulus, and microenvironmental conditions, yet cell cycle effects are routinely regressed out of single-cell EMT analyses. Here, we compare EMT between G1 and cycling (S/G2/M) cell states in two independent scRNA-seq datasets of TGF-{beta}-stimulated MCF10A mammary epithelial cells (varying dose and timepoint). G1 cells consistently show higher expression of EMT genes and upregulated RNA velocities than cycling cells, with the strongest upregulation in G1 EMT intermediate states. Consistent with the go-or-grow hypothesis, EMT and cell cycle programs inversely correlate; moreover, this anticorrelation extends to RNA velocity and strengthens with TGF-{beta} dose. We identify a 77-gene G1-specific EMT signature enriched for actin cytoskeletal and extracellular matrix genes that would otherwise be lost by regressing out cell cycle effects. This gene set prompts the hypothesis that, unconstrained by the cytoskeletal demands of mitosis, G1 cells have greater capacity to execute EMT. Further, we developed an EMT gene regulatory model coupled with a cell cycle module, and found through simulation that the model recapitulated this inverse EMT--cell cycle relationship. Using this model, we predict that cycle-selective chemotherapy enriches for the G1 intermediate state, which has high metastatic potential. Cell cycle phase thus ought not be regressed out of EMT states, given its influence on EMT.
Related
- 114 CXCL6 emerges as a novel marker of an immunosuppressive, angiogenic, and epithelial-mesenchymal transition (EMT)-enriched metastatic program in uveal melanoma (UM)
- Spatial confinement induces oscillatory migration of epidermal keratinocytes and forms a three-compartment epithelial structure with epithelial–mesenchymal transition dynamics
- Lack of centrosomes limits the epithelial-to-mesenchymal transition in human mammary cells
- Metallothionein-2A licenses an S100A8 alarmin program to drive epithelial-mesenchymal transition in pulmonary fibrosis
- DDB2 represses epithelial-to-mesenchymal transition and sensitizes pancreatic ductal adenocarcinoma cells to chemotherapy
BibTeX
@misc{mcdermott2026cell,
title = {{Cell cycling throttles epithelial--mesenchymal transition}},
author = {M. McDermott and A. Dey and R. Mehta and A. L. MacLean},
howpublished = {bioRxiv},
year = {2026},
month = nov,
doi = {10.64898/2026.11.05.764762},
url = {https://www.biorxiv.org/content/10.64898/2026.11.05.764762v1},
note = {CC BY-NC},
}
RIS
TY - UNPB
TI - Cell cycling throttles epithelial--mesenchymal transition
AU - M. McDermott
AU - A. Dey
AU - R. Mehta
AU - A. L. MacLean
PY - 2026
DA - 2026/11/05
PB - bioRxiv
DO - 10.64898/2026.11.05.764762
UR - https://www.biorxiv.org/content/10.64898/2026.11.05.764762v1
AB - Cell cycle phase is an understudied source of variation in gene expression. EMT is a case in point: this cell state transition that drives metastasis has been studied widely across tissue, stimulus, and microenvironmental conditions, yet cell cycle effects are routinely regressed out of single-cell EMT analyses. Here, we compare EMT between G1 and cycling (S/G2/M) cell states in two independent scRNA-seq datasets of TGF-{beta}-stimulated MCF10A mammary epithelial cells (varying dose and timepoint). G1 cells consistently show higher expression of EMT genes and upregulated RNA velocities than cycling cells, with the strongest upregulation in G1 EMT intermediate states. Consistent with the go-or-grow hypothesis, EMT and cell cycle programs inversely correlate; moreover, this anticorrelation extends to RNA velocity and strengthens with TGF-{beta} dose. We identify a 77-gene G1-specific EMT signature enriched for actin cytoskeletal and extracellular matrix genes that would otherwise be lost by regressing out cell cycle effects. This gene set prompts the hypothesis that, unconstrained by the cytoskeletal demands of mitosis, G1 cells have greater capacity to execute EMT. Further, we developed an EMT gene regulatory model coupled with a cell cycle module, and found through simulation that the model recapitulated this inverse EMT--cell cycle relationship. Using this model, we predict that cycle-selective chemotherapy enriches for the G1 intermediate state, which has high metastatic potential. Cell cycle phase thus ought not be regressed out of EMT states, given its influence on EMT.
ER -